JGC
NBIX icon

J. Goldman & Co’s Neurocrine Biosciences NBIX Stock Holding History

J. Goldman & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-53,000
Closed -$5.86M – 579
2025
Q1 		$5.86M Buy
+53,000
New +$6.71M 0.14% 191
2023
Q3 		– Sell
-39,400
Closed -$3.72M – 445
2023
Q2 		$3.72M Buy
+39,400
New +$3.85M 0.14% 167
2022
Q2 		– Sell
-6,800
Closed -$638K – 423
2022
Q1 		$638K Buy
+6,800
New +$576K 0.03% 278

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's NBIX Position: Q1 2026 in Review

J. Goldman & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2026, closing a stake of 53,303 shares — an estimated $7.56M sold.

J. Goldman & Co first reported a position in NBIX in Q1 2017 and held it in 13 quarters. The position peaked at $10.8M in Q1 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • J. Goldman & Co reported no remaining Neurocrine Biosciences position as of Q1 2026 after selling out during the quarter.
  • J. Goldman & Co sold 53,303 Neurocrine Biosciences shares in Q1 2026, an estimated $7.56M.
  • J. Goldman & Co first reported a position in Neurocrine Biosciences in Q1 2017 and held it in 13 quarters.
  • J. Goldman & Co's Neurocrine Biosciences position peaked at $10.8M in Q1 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.